March 18, 2021
HOLLY SPRINGS – Fujifilm Diosynth Biotechnologies has picked Holly Springs for a huge new drug manufacturing facility and the creation of hundreds of jobs paying average salaries of more than $95,000.
News that the company was considering North Carolina for the plant emerged in January. Texas also was considered for the plant, according to North Carolina officials.
A rendering of the future Holly Springs facility as provided by Fujifilm.
“There was strong competition for this, but he ended up in the right place,” Gov. Roy Cooper said of Fujifilm Diosynth Chief Executive Martin Meeson, during a Thursday afternoon ceremony in Holly Springs.
Meeson called the planned plant “a huge milestone” for the company, which is part of Japan-based Fuijifilm. It will be the largest cell culture contract development and manufacturing facility in North America, he said.
“The excitement is all about the amount of patients we will be able to target and the medicines we can bring to them in this facility that we’re creating,” he said. “This project is about looking to the future and how we will deliver medicines over the coming decades.”
Fujifilm Diosynth already has a plant in Morrisville, which makes more than 60 products, including treatments for prostate cancer, hereditary diseases and a potential coronavirus vaccine created by Novavax. Former President Donald Trump visited the plant last year to tout his administration’s vaccine development program.
The Holly Springs plant will create about 725 jobs between 2024 and 2028, according to an agreement made between Fujifilm Diosynth and the state Department of Commerce.